ChemicalBook > Articles Catagory List >Drugs >side-effects-of-finerenone-in-the-treatment-of-diabetic-nephropathy

Side effects of Finerenone in the treatment of diabetic nephropathy

Nov 21,2023

Introduction of Finerenone

Finerenone is a novel non-steroidal, highly selective salicorticoid receptor antagonist (MRA) with high binding affinity, high MR selectivity and short plasma half-life. It is approved for the treatment of chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2D). finerenone has been shown to improve multiple pathophysiological parameters in heart failure with preserved ejection fraction (HFpEF), with potentially beneficial effects.

Article illustration

Finerenone and Diabetic Nephropathy

Finerenone is a non-steroidal selective hydrocorticoid receptor antagonist. Studies have shown that Finerenone has more potent anti-inflammatory and antifibrotic effects than the steroidal salicorticoid receptor antagonists, reducing albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes mellitus, and reducing the urinary albumin/creatinine ratio in patients with CKD treated with a RAS blocker, while having a lesser effect on serum potassium levels than spironolactone.

Safety of Finerenone

In short-term studies in patients with CKD reduced ejection heart failure, with or without T2D, finerenone 20 mg appears to have a better renal outcome compared with spironolactone a better mortality outcome compared with eplerenone, with significantly lesser hyperkalemia compared to both spironolactone finerenone. In long-term studies in patients with CKD T2D, finerenone 10/20 mg significantly reduces progression renal disease reduced CV endpoints (especially heart failure hospitalization) compared to placebo. Finerenone has no effect HbA1c, body weight, sexual side effects including gynecomastia, has only a modest effect blood pressure. However, hyperkalemia leading to drug withdrawal was significantly higher with finerenone compared to placebo.

Findings in a study report of major adverse events after the use of fenugreek in patients with type 2 diabetes mellitus:finerenone increased risk for hyperkalemia by two times compared to placebo (RR = 2.03, 95% CI;1.82–2.26, I2 = 0%, p<0.00001), while it also significantly increased risk for hospitalization due to hyperkalemia (RR = 5.86, 95% CI 2.99 – 11.47, I2 = 0%, p<0.00001). We have also documented that finerenone did not significantly affect risk for development AKI (p = 0.94) or hospitalization in context AKI (p = 0.92). In addition, finerenone resulted in a marginally non-significant reduction in risk for all-cause death, equal to 10% (p = 0.05). However, extra caution is required, since hyperkalemia appears to be most important side effect with use finerenone, representing also main cause hospitalization due to a drug side effect.

References:

[1] D. PATOULIAS. MAJOR ADVERSE EVENTS WITH THE USE OF FINERENONE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A META-ANALYSIS OF CARDIOVASCULAR OUTCOME TRIALS[J]. Journal of Hypertension, 2022, 40 1: e158-e159. DOI:10.1097/01.hjh.0000836952.24656.9c.

[2] AWADHESH KUMAR SINGH. Finerenone in diabetic kidney disease: A systematic review and critical appraisal.[J]. Diabetes and Metabolic Syndrome-Clinical Research and Reviews, 2022, 16 10: 102638. DOI:10.1016/j.dsx.2022.102638.

1050477-31-0 FinerenoneSide effects diabetic nephropathy Finerenone
1050477-31-0

Related articles And Qustion

See also

12068-51-8 Spinel CrystalSpinel
Spinel Crystal
Nov 21, 2023
Finerenone
1050477-31-0 Finerenone
US $0.00-0.00/kg2024-11-26
CAS:
1050477-31-0
Min. Order:
1kg
Purity:
99%,single impurity<0.1
Supply Ability:
1 ton
Finerenone
1050477-31-0 Finerenone
US $0.00/g2024-11-19
CAS:
1050477-31-0
Min. Order:
1g
Purity:
98% HPLC
Supply Ability:
100g